Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Tackling the Achilles Heel of Immunotherapy: Validating imaging biomarkers and targeting the immunological niche of tumour hypoxia (HYPOXIMMUNO)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Prevention, Diagnosis and Treatment of Human Diseases
Panel description: Medical technologies and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions, pharmacology, preventative medicine, epidemiology and public health, digital medicine
Countries involved: France,Netherlands
Call: ERC Advanced Grant (ERC-2015-AdG, 2015)
Start date: 2016-12-01
End date: 2023-05-31
Duration (months): 78.0
Total project cost (EUR): 2499399.0
EU funding (EUR): 2402499.0
Participants: 2
Project status: SIGNED

Lung cancer is the most common cause of death from cancer worldwide with 1.59 million deaths annually and it places the highest economic burden of all cancers on the EU at €18.8billion. These figures call for a major transformation of the therapeutic management of lung cancer. The recent developments in immunotherapy give new hope. At present a significant minority of patients benefit from immune therapy, which remains not curative when delivered alone. It is thus clear that improving the efficacy of immune therapy is needed as well as the identification of predictive biomarkers. Combining immunotherapy with radiotherapy improves effectiveness, but resistance is still common, most probably because of hypoxia. In HYPOXIMMUNO, we will open up a new paradigm in treating metastatic NSCLC. I will provide for the first time (pre)clinical proof of concept of (i) highly innovative CT-based radiomics and PET-hypoxia imaging patient stratification tools and (ii) a tri-modal curative hypoxia-targeting treatment strategy that complements current immunotherapy and radiotherapy approaches. This tri-modal curative treatment strategy is based on (1) high precision Stereotactic Radiotherapy (SABR) to kill cancer cells and trigger the immune system, combined with (2) a hypoxia-activated prodrug to target the hypoxic tumour cells resistant to immunotherapy and (3) a promising and innovative tumour specific antibody (Ab)-based immunotherapy (immunocytokine L19-IL2 to “push the accelerator” with or without a checkpoint inhibitor to “release the break”) to form a powerful synergistic immuno-oncology strategy. In HYPOXIMMUNO, I envision to lay the foundation for the next breakthrough in oncology, by improving patient selection and developing highly innovative cancer therapies that target hypoxia, to improve the quality of life and prolong survival of cancer patients, in particular patients with metastatic NSCLC (watch the animation summarising the project: https://youtu.be/oP9Gp4a0b_Q).

Keywords: hypoxia,radiation,immunotherapy,lung cancer,metastatic disease,stereotactic ablative radiotherapy,hypoxia activated prodrug,biomarker,patient stratification,radiomics,immunocytokines
Dissecting the interplay between the dynamics of immune responses and pathogen proliferation in vivo (ImmProDynamics)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Immunity, Infection and Immunotherapy
Panel description: The immune system, related disorders and their mechanisms, biology of infectious agents and infection, biological basis of prevention and treatment of infectious diseases, innovative immunological tools and approaches, including therapies
Countries involved: Germany
Call: ERC Starting Grant (ERC-2016-STG, 2016)
Start date: 2017-03-01
End date: 2022-02-28
Duration (months): 60.0
Total project cost (EUR): 1499525.0
EU funding (EUR): 1499525.0
Participants: 1
Project status: CLOSED

Pathogen proliferation has profound implications for its persistence, treatment strategies, and the induction and execution of protective immune responses. In vivo, pathogen proliferation rates are heterogenic, confronting the immune system with a variety of microbial physiological states. It is unknown if, and by what molecular mechanism, the immune response can distinguish these different states on a cellular level. Also, understanding the link between pathogen proliferation and immune cell dynamics could provide critical information on how infections can be controlled, and how to counteract pathogen persistence and antibiotic resistance. However, this question has never been addressed due to difficulties in studying the dynamics of immune cells and at the same time probing pathogen proliferation. In this project, we will make use of a novel in vivo reporter system that I have developed, in order to determine the role of the pathogen's proliferation for its interaction with the immune system. Specifically, we will (1) determine the tissue niche in which the pathogen proliferates, (2) investigate the differential dynamics of phagocyte-pathogen- and of T cell-APC-interactions related to pathogen proliferation rate, (3) manipulate the relationship between pathogen proliferation and immune cell dynamics by using proliferation-deficient mutants and optogenetic pathogen inactivation, (4) identify signaling pathways that are differentially induced in cells infected by high versus low proliferating pathogens, and test their involvement in differential immune cell dynamics related to pathogen proliferation. ImmProDynamics will for the first time provide insights into how cells of the immune system react to distinct pathogen proliferative states in vivo. This will greatly expand our knowledge of host-pathogen interactions, which will be critical for the design of efficient vaccines and antimicrobial therapy.
Predicting Response to Depression Treatment (PReDicT)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: SME instrument
Countries involved: United Kingdom
Call: Clinical research for the validation of biomarkers and/or diagnostic medical devices (H2020-SMEINST-1-2014, 2014)
Start date: 2015-02-01
End date: 2015-05-31
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Depression is a leading cause of disability and produces a greater decrement in health than other common chronic diseases such as angina, arthritis, asthma and diabetes. In Europe, it is estimated that 7.2% of the disease burden is caused by depression with associated costs of €118 billion. It generally takes months before clinicians are able to identify an effective antidepressant treatment for individual patients and during this period a patients’ ability to work and function socially is severely impaired by their illness. We will address this problem using the Primary Care –Emotional Test Battery (PC-ETB) a medical device that is sensitive to changes in negative emotional bias, an early biomarker for the effectiveness of antidepressant treatment. Identifying early, rather than late in treatment, if an antidepressant is working will significantly reduce the time required for the patient to get better and return to normal life. The PC-ETB has been developed from a more extensive product battery that we provide to the pharmaceutical industry for drug development. In Phase 1 we will: (i) Assess the feasibility of using the PC-ETB in primary care in Europe; (ii) Determine how to set up a multinational medical device clinical investigation in Europe; (iii) Expand a health economic assessment conducted in the UK to include other major European countries and demonstrate the healthcare and societal benefits across Europe; (iv) Develop a commercialisation strategy across the major European countries by conducting a market research assessment of the market size, route to adoption, pricing and reimbursement mechanisms. In Phase 2 of the project we will conduct clinical validation of multi-lingual versions of the PC-ETB in a number of European countries. This innovative project is designed to complete the clinical validation of the PC-ETB and enable its launch as an internet delivered product to improve the management and treatment of depression across the European market.

Keywords: predicting early response to antidepressant treatment for depression
Developing 2-photon optical imaging for neural-network studies in medial entorhinal cortex of freely moving mice (ANAT-MEC)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Norway
Call: Individual Fellowships (H2020-MSCA-IF-2018, 2018)
Start date: 2019-05-01
End date: 2021-04-30
Duration (months): 24.0
Total project cost (EUR): 214158.72
EU funding (EUR): 214158.72
Participants: 1
Project status: CLOSED

The medial entorhinal cortex (MEC) and the adjacent pre- and parasubiculum are thought to create an internal map of self-position that animals may use for goal-directed navigation. This map uses a set of functionally specific and largely non-overlapping cell types: grid cells, border cells, speed cells, object-vector cells, and head-direction cells. The presence of multiple distinct functional cell types, matched in specificity only by cell populations in some of the sensory and motor cortices, allows us to examine input-output transformations and computational algorithms in association cortices with unprecedented power and detail. In order to examine these algorithms, however, an obvious and crucial first step is to map the division of function across cells in anatomical space. This requires recording of hundreds of cells at the same time in freely-behaving animals exploring open spatial environments. Unfortunately the absence of appropriate methods for neural recording at the population level has so far prevented a clear understanding of the broader organization of multi-cell-type and multi-layer networks of MEC, at both micro and macro scales. During my PhD, I invented a technique called “fast high-resolution miniaturized two-photon microscopy (FHIRM-TPM)”, which, through the use of a portable light-weight (2g) two-photon microscope, allows animals to move freely while large scale, single-cell-resolution calcium imaging is performed. In ANAT-MEC, I will refine this optical imaging method to study neural activity during spatial navigation in two-dimensional environments. I shall characterize in detail the anatomical organization of distinct cell types in MEC while mice engage in naturalistic, exploratory behavior in open spaces. Besides shedding light on this specific question, the project will – by developing a new technology - also open doors to unravel fundamental mechanisms of neural code formation in the mammalian space circuit.

Keywords: medial entorhinal cortex,grid cell,two photon microscopy,miniature microscope,free moving imaging
Robot Learning for Unprecedented Quality and Efficiency Improvements in the Manufacturing Industry (OPTOFORCE)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Nanotechnologies
Action type: SME instrument
Countries involved: Hungary
Call: Accelerating the uptake of nanotechnologies advanced materials or advanced manufacturing and processing technologies by SMEs (H2020-SMEINST-1-2016-2017, 2017)
Start date: 2017-12-01
End date: 2018-03-31
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

The need to widen the range of tasks that robots can handle and the emergence of the so-called fenceless robotic systems that can safely work alongside humans have required the development of tactile sensors that can detect changes in the surroundings throughout physical contact and force sensing, allowing improved safety. As a result, we are witnessing a growing demand of force and torque sensors in industries such as automotive, food and beverage, packaging, and pharmaceutical. On the other hand, all the sensing equipment integrated into the manufacturing processes generates enormous volumes of data within industrial control systems that is currently underused. However, there is an increasing need to exploit this data to reduce operating costs, improve reliability, and increase productivity. Likewise, most common industrial robots do not exploit the data they generate to improve their efficiency. They are programmed once and are unable to improve. OptoForceX aims at providing plant managers with unparalleled F/T sensors that will enhance automation strategies and allow the exploitation of the production data generated on the manufacturing floor using state-of-the-art machine learning techniques. Manufacturers will be able to capture/collect and store vast amounts of data/information from high-quality sensors monitoring the manufacturing process. They will improve the performance of manufacturing robots by 10-20%, improve cycle time up to 15% and reduce quality inspection resources and maintenance efforts by 60%. We therefore offer manufacturers a valuable tool to enhance their manufacturing lines. We forecasted for this project a cumulative revenue of €51.61M for the first 3 years of commercialization, with a cumulative profit of €10.32M. We projected a ROI of 3.52. The payback period is reached during the 2nd commercialization year.

Keywords: robotic sensors,machine learning,big data,indutry 4 0,increased efficiency
Seabed Imprint of Dense Shelf Water Cascading (SIDEW)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: United Kingdom
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2014, 2014)
Start date: 2016-04-01
End date: 2018-03-31
Duration (months): 24.0
Total project cost (EUR): 195454.8
EU funding (EUR): 195454.8
Participants: 1
Project status: CLOSED

Dense shelf water cascading (DSWC) is an atmosphere-driven seasonal phenomenon that occurs in marine regions off Europe and elsewhere. DSWC starts when surface waters over the continental shelf become denser than surrounding waters and sink, generating a near-bottom turbulent flow that moves downslope along the seabed. This process contributes to the deep ocean ventilation and in the global thermohaline circulation (and hence global climate), and involves the massive transfer of energy and matter from shallow to deep waters. While frequently cited as a possible control of the seafloor morphology, there is a lack of studies isolating the DSWC geomorphic effects from other processes known to shape continental margins. This project aims to study the seafloor imprint of DSWC using high-resolution field data and interdisciplinary concepts. The primary focus will be on multibeam bathymetry data sets from 6 areas affected by DSWC. 8 leading research institutions committed to provide the data required. The main expected results are: 1) a better understanding of the physical processes involved in the propagation of DSWC flows, 2) a quantification of their capacity to erode and deposit sediment, and 3) a characterization of the sensitivity of DSWC formation and distribution to climate change in Polar Regions. The host institution expertise on the links between ice sheet dynamics, climate change and marine geological records will be crucial for the training of the applicant and for the success of the project. The planned secondment will add a numerical modelling component so that an in-depth knowledge of the physical processes involved in the propagation of DSWC is achieved. This pioneering work will extend European leadership in the study of DSWC, address EU challenges in the Horizon 2020 programme, and be of interest to industries exploring for natural resources. The project represents an extraordinary opportunity for the applicant to develop technically and professionally.

Keywords: dense shelf water cascading,geomorphology,glaciology,sedimentology,oceanography,fluid dynamics,climate change,multibeam bathymetry
Suppresion of adaptive immunity by the Salmonella effector SteD (SupaSteD)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: United Kingdom
Call: Individual Fellowships (H2020-MSCA-IF-2016, 2016)
Start date: 2017-09-01
End date: 2019-08-31
Duration (months): 24.0
Total project cost (EUR): 195454.8
EU funding (EUR): 195454.8
Participants: 1
Project status: CLOSED

In this project, I propose to characterize the influence of SteD, an effector of a globally important bacterial pathogen Salmonella enterica, on T cell development, and its potential therapeutic application. In the mouse model of S. enterica infection, the onset of the specific immune responses is delayed significantly in comparison to other bacterial pathogens. Recent work by the group of Prof. Holden, who is the supervisor of this project, a world leader in the field of Salmonella pathogenesis and the Director of the MRC Centre for Molecular Bacteriology and Infection (MRC-CMBI) at Imperial College London, identified SteD, an effector of the Type III Secretion System (T3SS) encoded by Salmonella pathogenicity island 2 (SPI-2), as the first example of a virulence factor that reduces surface-localised mature Major Histocompatibility Complex class II (MHCII) levels in Dendritic Cells. In addition, I have found an increased activation of T cells following infection of C57BL/6 mice with S. enterica serovar Typhimurium (STm) ΔsteD mutant in comparison to wild-type STm, thereby showing that SteD is an important modulator of adaptive immunity in vivo. SteD and/or its gene have a high chance of having therapeutic application. I also have obtained preliminary evidence indicating that SteD has additional functions in the manipulation of antigen-presenting cells. Therefore, I propose to use both the acute and chronic mouse models of Salmonella infection to further characterize the influence of SteD on T cell development. Furthermore, I will investigate the mechanistic and physiological significance of natural variation in the amino acid sequence of SteD among a broad range of S. enterica serovars, including the typhoid fever-causing human-adapted serovars Typhi and Paratyphi. Finally, I will explore the possible use of SteD in new formulations of DNA vaccines. These studies will provide important knowledge for the clinical application of this newly described T3SS effector.

Keywords: salmonella
GN4-2 Research and Education Networking - GÉANT (GN4-2)

Framework: Horizon 2020 — Excellent Science
Programme: Research Infrastructures
Theme: Research infrastructures
Destination: GÉANT Partnership
Action type: Specific Grant agreement
Countries involved: Germany,Estonia,Italy,Austria,Spain,Israel,Albania,Armenia,Ukraine,Azerbaijan,Ireland,Malta,Cyprus,Slovakia,Serbia,Lithuania,Greece,North Macedonia,Belgium,Bulgaria,Hungary,Slovenia,Belarus,Türkiye,Croatia,Poland,Romania,Switzerland,Moldova, Republic of,Georgia,Latvia,France,Czechia,Netherlands,United Kingdom,Montenegro,Portugal,Luxembourg,Denmark,United Kingdom
Call: Research and Education Networking – GÉANT (H2020-IBA-SGA-INFRA-GEANT-2016, 2016)
Start date: 2016-05-01
End date: 2020-01-31
Duration (months): 45.0
Total project cost (EUR): 100480095.5
EU funding (EUR): 59000000.0
Participants: 43
Project status: CLOSED

GN4-2 is the proposed project for the second Specific Grant Agreement under the 68-month Framework Partnership Agreement (FPA) established between the GÉANT Consortium and the European Commission in April 2015.This second phase of implementing the FPA will raise European research to the next level by promoting scientific excellence, access and re-use of research data. It will also drive European-wide cost efficiencies in scientific infrastructure by promoting interoperability with other e-infrastructures on an unprecedented scale. The FPA objective for the GÉANT Partnership is to contribute to effective European research by making Europe the best-connected region in the world. GÉANT must offer European researchers the network, communications facilities and application access that ensure the digital continuum necessary to conduct world-class research in collaboration with their peers, regardless of geographical location. GÉANT will maintain the operational excellence of the established GÉANT services, while achieving economies on the costs of the backbone network. The reliable, secure and state-of-the-art network services offered to researchers and other network users across Europe will remain exceptional. Massive data-transfer capacities required by extreme-scale instruments and by the penetration of big data in many areas of science will be prototyped with due consideration to the specific security and deployment challenges. Trust and identity is also prioritised with the introduction of a scalable operational model and with user requirements addressed in close concertation with the AARC and proposed AARC2 projects. GN4-2 developments are also guided by the vision of a future where a set of coherent and integrated European e-infrastructure services will offer convenient, seamless access for end-users through a common service catalogue, and facilitating the adoption of services offered by new e-infrastructure developments, such as the European Open Science Cloud.

Keywords: networks,research networking,mult domain networking,communication networks,secure,trust,innovation,media,information society,computer sciences,e infrastructure,communication commons